MRKR

Marker Therapeutics, Inc. (MRKR) | Rumor.io

Marker Therapeutics

MRKR

Attention (50-day avg)0%

Attention rank (50-day avg)#4,302

Bullish sentiment (50-day avg)100%

Price to earnings ratio-1.42

Market capitalization18.8M

Earnings per share-0.38

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-12.2M

Social

What share of all stock conversation is about MRKR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jan 8

$MRKR is expected to reach at least double digits with the current prices still being very low.
A "golden cross" has occurred, indicating a potential transition from a downtrend to a new uptrend and triggering interest from technical traders.
MRKR has rallied nearly 25% over the past four weeks, adding to its technical strength, with analysts currently listing it as a #1 (Strong Buy).

Generated by AI

Sentiment

Of the messages about MRKR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	94.83% +13.17
Bearish	—	0%	0% 0	5.17% -13.17

Bullish· Jan 8

Marker Therapeutics' ($MRKR) recent technical indicator, the golden cross, suggests potential upward momentum in price.
The company's combination of Multi-Antigen Targeted T cells with frontline chemotherapy (Arm A) is a promising approach.
$MRKR's current low prices and positive news indicate the stock has a lot of potential and is likely to reach double digits in the near future.

Bearish· Aug 27

The stock's price drop from $2 to $1 may indicate a blowoff top, and further decline is expected.
The company's lymphoma results, while positive, have been met with aggressive selling, likely due to anticipated dilution news.
The stock's price action is being driven by algo manipulation, and a breakdown below current levels is expected.

Generated by AI

Topics

Of the messages about MRKR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	21.88%
Macro	—	—	—	1.04%
Technical Analysis	—	—	—	21.88%
Announcements	—	—	—	53.65%
Controversies	—	—	—	0%
Earnings	—	—	—	1.56%

Announcements· Aug 26

Marker Therapeutics, Inc. (MRKR) reported promising Phase 1 APOLLO study results for MT-601, a Multi-Antigen Recognizing T-cell therapy for relapsed lymphoma, with a 66% objective response rate and 50% complete response rate.
Analysts are reiterating a Buy rating on Marker Therapeutics, citing its innovative MAR-T cell therapy and robust financial position, with a price target of $12.50.
The company has secured over $13 million in non-dilutive funding to advance its lead product, MT-601, in treating metastatic pancreatic cancer and non-Hodgkin's lymphoma, with encouraging preliminary data from the Phase 1 APOLLO study.

Technical Analysis· Jul 18

The market appears to be at a stalemate, with low volume and no big sellers, setting the stage for a potential rebound.
The stock has formed a double bottom pattern, which is a bullish sign, and the author is confident that it will move up to $4 or more.
The stock is currently oversold and due for a bounce, with the author suggesting that buyers should accumulate and hold indefinitely.

Generated by AI

Community

Of the messages about MRKR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	71.1%
Newcomers	—	0%	0%	28.9%

Regulars· Dec 11

A participant in the APOLLO study involving Marker Therapeutics' MT-601 treatment for lymphoma patients who failed or are ineligible for anti-CD19 CAR T cell therapy has maintained a complete response for at least six months.
The FDA is investigating CAR T cell therapies for the risk of potential induction of secondary cancers, a concern also noted by Marker Therapeutics, Inc.
Marker Therapeutics, Inc. has achieved a sustained complete response in a significant breakthrough for immunotherapy, with one study participant relapsing within 90 days after CAR T cell therapy but maintaining a complete response for at least six months after MT-601 treatment.

Newcomers· Jan 8

New investors are optimistic about Marker Therapeutics, with one user predicting its stock price will continue to rise.
Some newcomers are drawn to Marker Therapeutics due to its potential in the biotech sector, with one user noting its focus on cancer treatments.
Another user is focused on the company's unique approach to cancer immunotherapy, citing its potential to revolutionize treatment options.

Generated by AI

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead program, MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therap

7d agoYahoo Finance

Analysts Are Bullish on These Healthcare Stocks: Marker Therapeutics (MRKR), Tenax Therapeutics (TENX)

Detailed price information for Marker Therapeutics Inc (MRKR-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about MRKR also mention

#	Name	Attention
1	Immuneering Corp. Class A Common StockIMRX	0%0
2	WEBs QQQ Defined Volatility ETFDVQQ	0%0
3	CWBR - CohBar, Inc.	——
4	BG Staffing IncBGSF	0%new
5	Mega Matrix Inc.MPU	0%0
6	Palvella Therapeutics, Inc.PVLA	0%new
7	Monarch Casino & Resort, Inc.MCRI	0%0
8	AIFU Inc. Class A Ordinary ShareAIFU	0%+0
9	Jowell Global Ltd.JWEL	0%0
10	Uni-Fuels Holdings Ltd.UFG	0%0

Marker Therapeutics, Inc.

Healthcare
Biotechnology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing T cell-based immunotherapies for blood cancers and solid tumors. Its core platform uses non-genetically engineered tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of creating broader anti-cancer activity. The company’s current pipeline includes product candidates such as MT-601, being studied in lymphoma and pancreatic cancer, and MT-401-OTS, being evaluated in acute myeloid leukemia and myelodysplastic syndromes. Marker Therapeutics also explores peptide-based vaccine approaches as part of its cancer treatment portfolio. Headquartered in Houston, Texas, the company operates in the biotechnology sector and serves the specialized area of cell therapy research and development, where its work supports the advancement of next-generation treatments for difficult-to-treat malignancies.

Website

Location

2450 Holcombe Blvd

Houston, TX, 77021

United States

Social

What share of all stock conversation is about MRKR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jan 8

$MRKR is expected to reach at least double digits with the current prices still being very low.
A "golden cross" has occurred, indicating a potential transition from a downtrend to a new uptrend and triggering interest from technical traders.
MRKR has rallied nearly 25% over the past four weeks, adding to its technical strength, with analysts currently listing it as a #1 (Strong Buy).

Generated by AI

Sentiment

Of the messages about MRKR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	94.83% +13.17
Bearish	—	0%	0% 0	5.17% -13.17

Bullish· Jan 8

Marker Therapeutics' ($MRKR) recent technical indicator, the golden cross, suggests potential upward momentum in price.
The company's combination of Multi-Antigen Targeted T cells with frontline chemotherapy (Arm A) is a promising approach.
$MRKR's current low prices and positive news indicate the stock has a lot of potential and is likely to reach double digits in the near future.

Bearish· Aug 27

The stock's price drop from $2 to $1 may indicate a blowoff top, and further decline is expected.
The company's lymphoma results, while positive, have been met with aggressive selling, likely due to anticipated dilution news.
The stock's price action is being driven by algo manipulation, and a breakdown below current levels is expected.

Generated by AI

Topics

Of the messages about MRKR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	21.88%
Macro	—	—	—	1.04%
Technical Analysis	—	—	—	21.88%
Announcements	—	—	—	53.65%
Controversies	—	—	—	0%
Earnings	—	—	—	1.56%

Announcements· Aug 26

Marker Therapeutics, Inc. (MRKR) reported promising Phase 1 APOLLO study results for MT-601, a Multi-Antigen Recognizing T-cell therapy for relapsed lymphoma, with a 66% objective response rate and 50% complete response rate.
Analysts are reiterating a Buy rating on Marker Therapeutics, citing its innovative MAR-T cell therapy and robust financial position, with a price target of $12.50.
The company has secured over $13 million in non-dilutive funding to advance its lead product, MT-601, in treating metastatic pancreatic cancer and non-Hodgkin's lymphoma, with encouraging preliminary data from the Phase 1 APOLLO study.

Technical Analysis· Jul 18

The market appears to be at a stalemate, with low volume and no big sellers, setting the stage for a potential rebound.
The stock has formed a double bottom pattern, which is a bullish sign, and the author is confident that it will move up to $4 or more.
The stock is currently oversold and due for a bounce, with the author suggesting that buyers should accumulate and hold indefinitely.

Generated by AI

Community

Of the messages about MRKR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	71.1%
Newcomers	—	0%	0%	28.9%

Regulars· Dec 11

A participant in the APOLLO study involving Marker Therapeutics' MT-601 treatment for lymphoma patients who failed or are ineligible for anti-CD19 CAR T cell therapy has maintained a complete response for at least six months.
The FDA is investigating CAR T cell therapies for the risk of potential induction of secondary cancers, a concern also noted by Marker Therapeutics, Inc.
Marker Therapeutics, Inc. has achieved a sustained complete response in a significant breakthrough for immunotherapy, with one study participant relapsing within 90 days after CAR T cell therapy but maintaining a complete response for at least six months after MT-601 treatment.

Newcomers· Jan 8

New investors are optimistic about Marker Therapeutics, with one user predicting its stock price will continue to rise.
Some newcomers are drawn to Marker Therapeutics due to its potential in the biotech sector, with one user noting its focus on cancer treatments.
Another user is focused on the company's unique approach to cancer immunotherapy, citing its potential to revolutionize treatment options.

Generated by AI

Marker Therapeutics

Social

Jan 8

Sentiment

Bullish· Jan 8

Bearish· Aug 27

Topics

Announcements· Aug 26

Technical Analysis· Jul 18

Community

Regulars· Dec 11

Newcomers· Jan 8

News

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

12 Health Care Stocks Moving In Tuesday's After-Market Session

H.C. Wainwright reiterates Marker Therapeutics stock rating at buy

Wainwright reiterates Buy on Marker Therapeutics stock, $10 target

Analysts Are Bullish on These Healthcare Stocks: Marker Therapeutics (MRKR), Tenax Therapeutics (TENX)

Also Discussed

Marker Therapeutics, Inc.

Company Information

Location

News

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

12 Health Care Stocks Moving In Tuesday's After-Market Session

H.C. Wainwright reiterates Marker Therapeutics stock rating at buy

Wainwright reiterates Buy on Marker Therapeutics stock, $10 target

Analysts Are Bullish on These Healthcare Stocks: Marker Therapeutics (MRKR), Tenax Therapeutics (TENX)

Also Discussed

Social

Jan 8

Sentiment

Bullish· Jan 8

Bearish· Aug 27

Topics

Announcements· Aug 26

Technical Analysis· Jul 18

Community

Regulars· Dec 11

Newcomers· Jan 8